Tau and glial fibrillary acidic proteins should also undergo further evaluation as potential biomarkers and surrogate endpoints for clinical trials of therapeutic agents for ALSP. This evidence concerns the gene MAPT and Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia.